{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:45:36Z","timestamp":1794343536998,"version":"4.9.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"ASCO Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.esmoop.2026.108584","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:06:02Z","timestamp":1791896762000},"page":"108584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent\/metastatic head and neck squamous-cell carcinomas"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5008-8854","authenticated-orcid":false,"suffix":"Jr","given":"W.N.","family":"William","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8711-1699","authenticated-orcid":false,"given":"M.S.","family":"Kies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.R.","family":"Blumenschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.S.","family":"Glisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-4160","authenticated-orcid":false,"given":"F.M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-156X","authenticated-orcid":false,"given":"L.P.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108584_bib1","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108584_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","article-title":"Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Cohen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib5","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1158\/1078-0432.CCR-05-1247","article-title":"Phase II trial of gefitinib 250 mg daily in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108584_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib7","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck","volume":"27","author":"Stewart","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108584_bib9","article-title":"Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and\/or metastatic squamous-cell carcinoma of the head and neck","volume":"23","author":"Bel\u00f3n","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib10","doi-asserted-by":"crossref","first-page":"526-e49","DOI":"10.1634\/theoncologist.2017-0661","article-title":"Single-arm, phase II study of cisplatin, docetaxel, and erlotinib in patients with recurrent and\/or metastatic head and neck squamous cell carcinomas","volume":"23","author":"William","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108584_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncponc1321","article-title":"Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck","volume":"6","author":"William","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108584_bib13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S1470-2045(14)70402-4","article-title":"Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data","volume":"15","author":"Rossi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108584_bib15","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1200\/JCO.2002.20.6.1593","article-title":"Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck","volume":"20","author":"Glisson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2001.19.1.265","article-title":"Clinical trial designs for cytostatic agents: are new approaches needed?","volume":"19","author":"Korn","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib17","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1200\/JCO.2001.19.6.1848","article-title":"Clinical trial designs for the early clinical development of therapeutic cancer vaccines","volume":"19","author":"Simon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib18","article-title":"Triple oral metronomic chemotherapy versus chemotherapy of physician discretion after failure of platinum-based therapy in advanced head and neck cancer: a phase III randomized study (METRO-CHASE Study)","volume":"11","author":"Kapoor","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib19","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.01076","article-title":"Phase I\/II study of palliative triple metronomic chemotherapy in platinum-refractory\/early-failure oral cancer","volume":"37","author":"Patil","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib20","article-title":"A comparative assessment of the efficacy and toxicity profiles of dual and triple oral metronomic chemotherapy in advanced head and neck cancers in a tertiary care center","volume":"17","author":"Nair","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.esmoop.2026.108584_bib21","article-title":"Integrating metronomic therapy with standard chemotherapy in advanced unresectable head and neck cancer: a randomized trial addressing global cancer care equity (METRO PLUS)","volume":"12","author":"Kapoor","year":"2026","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib22","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.108584_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","article-title":"EGFR TKI combination with immunotherapy in non-small cell lung cancer","volume":"16","author":"Ahn","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.esmoop.2026.108584_bib25","article-title":"Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial","volume":"47","author":"Marimuthu","year":"2026","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.esmoop.2026.108584_bib26","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.108584_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108584_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.108584_bib29","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/annonc\/mdx344","article-title":"Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and\/or metastatic head and neck cancer","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib30","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-25-0073","article-title":"INTERLINK-1: a phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"31","author":"Fayette","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108584_bib31","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.32762","article-title":"A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent\/metastatic head and neck squamous cell carcinoma","volume":"126","author":"Kochanny","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108584_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdt574","article-title":"Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial","volume":"25","author":"Vermorken","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib34","doi-asserted-by":"crossref","first-page":"S1557","DOI":"10.1016\/j.annonc.2024.10.434","article-title":"411MO petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): phase II trial","volume":"35","author":"Le Tourneau","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib35","doi-asserted-by":"crossref","unstructured":"Chung CH, Hanna GJ, Zandberg DP, et al. Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: updated results from an expansion cohort of an open-label, multicenter, phase 1\/1b trial. J Clin Oncol. 205;43(suppl 16):6017.","DOI":"10.1200\/JCO.2025.43.16_suppl.6017"},{"key":"10.1016\/j.esmoop.2026.108584_bib36","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ijrobp.2016.03.011","article-title":"Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the RTOG experience","volume":"95","author":"Bar-Ad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.108584_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00280-021-04328-9","article-title":"Cetuximab-induced rash is associated with overall survival in patients with recurrent\/metastatic squamous cell carcinoma of head and neck","volume":"88","author":"G\u00f6ksu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2026.108584_bib38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fonc.2018.00616","article-title":"Predictive value of cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and NECK","volume":"8","author":"Uozumi","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib39","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.oraloncology.2009.05.637","article-title":"Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck","volume":"45","author":"Cohen","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2015.4364","article-title":"Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial","volume":"2","author":"William","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib41","article-title":"Mechanisms underlying skin disorders induced by EGFR inhibitors","volume":"2","author":"Holcmann","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib42","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/jamaoncol.2025.3136","article-title":"Emerging EGFR-targeted therapy in head and neck cancer: a review","volume":"11","author":"Hwang","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.108584_bib43","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/hed.28152","article-title":"Phase II trial of chemotherapy, cetuximab, and erlotinib in patients with metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"47","author":"Bhatia","year":"2025","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2026.108584_bib44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","article-title":"EGFR inhibition enhances the cellular uptake and antitumor activity of the HER3 antibody-drug conjugate HER3-DXd","volume":"82","author":"Haikala","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108584_bib45","series-title":"New therapeutic combination to enhance endocytosis of antibodies and nucleic-acid aptamers targeting EGFR in glioblastoma cells","author":"Cruz Da Silva","year":"2024"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:02:17Z","timestamp":1794340937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926025299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2059702926025299"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108584","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent\/metastatic head and neck squamous-cell carcinomas","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108584"}}